Developer docs
API playgroundTry for free, no card

Search company profiles

SpineThera

Full company profile

uuid0002umj

Namestring
SpineThera
Legal namestring
SpineThera, Inc.
Websiteurl
spinethera.com
Company typeenum
Private
Founded yearint
2012
Descriptiontext

SpineThera is a clinical-stage pharmaceutical company developing sustained-release injectable drugs for pain management. Its lead asset, SX600, is a novel formulation of dexamethasone built on the proprietary Faros™ drug delivery platform, designed to provide months-long sustained release from a single epidural injection for the treatment of lumbar radicular pain (sciatica). The company is led by founder and CEO Jeff Missling and Chief Medical Officer William Houghton. Notably, no FDA-approved drug currently exists for epidural injection to treat lumbar radicular pain, positioning SX600 as a potential first-in-class therapy for what the company characterizes as the most common cause of disability in the United States and the most expensive indication in healthcare.

The company's technology foundation is the Faros™ sustained-release drug delivery platform, protected by 7 issued US patents as of November 2024. SX600 completed Phase 2 clinical trials demonstrating clinically meaningful and durable pain reduction from a single injection; however, an additional non-rodent toxicology study is required before opening an IND to advance into Phase 3. SpineThera operates as a subsidiary within Frenelle Pharma's hub-and-spoke model, alongside portfolio companies Frenelle PBC and Anumio. In April 2024, SpineThera divested its manufacturing capabilities to ProMed Pharma while retaining an option for IP licensing, indicating a transition to an asset-light, R&D-focused operating model.

SpineThera's business model is pre-commercial and currently revenue-free. Historical funding has come from exempt securities offerings (a $4M Form D filed in June 2021, with $1.215M sold) and a $5M Department of Defense grant awarded in April 2022. Upon any future FDA approval, distribution is expected to flow through specialty pharmacies, hospital formularies, and pain management clinics. End customers are patients with lumbar radicular pain and the pain management specialists who administer treatment. The company has begun exploring adjacent applications of the Faros™ platform through a June 2024 collaboration with Mayo Clinic in substance abuse disorder treatment, signaling intent to monetize the delivery technology beyond its original indication.

Short descriptiontext

SpineThera is a clinical-stage pharmaceutical company developing SX600, a sustained-release dexamethasone epidural injection using its proprietary Faros™ drug delivery platform to treat lumbar radicular pain (sciatica), an indication with no current FDA-approved drug therapy.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
sustained-release pharmaceuticals, epidural injection therapy, lumbar pain treatment, drug delivery platforms, corticosteroid formulations
Industry2 codes
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)
Product category
Pain Management Pharmaceuticals
Social media profiles2 records
Revenue model1 record
1Pharmaceutical Product Sales
TypeOne Time License
Description

Pre-revenue clinical-stage company. Revenue will be generated through sales of FDA-approved pharmaceutical products, specifically SX600 for lumbar radicular pain treatment upon regulatory approval.

frenellepharma.com
Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1Faros™
Description

Proprietary technology platform used for sustained-release drug delivery in SpineThera's lead asset SX600.

frenellepharma.com
+1 more record
Core offering1 text field

SpineThera is developing SX600, a novel sustained-release formulation of dexamethasone administered as a single epidural injection for the treatment of lumbar radicular pain (sciatica). The product is built on the proprietary Faros™ drug delivery platform, which enables months-long therapeutic release of dexamethasone from a single injection, eliminating the need for repeated corticosteroid procedures. SX600 has completed Phase 2 clinical trials demonstrating clinically meaningful and durable pain reduction.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection in Phase 2 trial
Product overview1 text field

SpineThera is a clinical-stage pharmaceutical company that operates as a subsidiary of Frenelle Pharma. The company is developing SX600, a novel formulation of dexamethasone utilizing the proprietary Faros™ sustained-release drug delivery technology platform. SX600 is designed as an epidural injection for lumbar radicular pain (sciatica) and has completed Phase 2 clinical trials. Currently, there is no FDA-approved drug for epidural injection to treat lumbar radicular pain, representing a potential first-in-class opportunity. The company's pipeline progresses from preclinical through Phase 3 stages.

Product and service2 records
1SX600
CategoryPain Management Pharmaceutical Product
Description

Novel sustained-release formulation of dexamethasone using Faros™ technology, developed as a single epidural injection for the treatment of lumbar radicular pain (sciatica). Designed to deliver months-long sustained-release dexamethasone from a single injection, eliminating the need for repeated corticosteroid procedures. Completed Phase 2 clinical trials with positive efficacy data. Intended for prescription and administration by pain management specialists and healthcare providers.

2Faros™ Drug Delivery Technology Platform
CategoryDrug Delivery Technology Platform
Description

Proprietary sustained-release drug delivery technology platform enabling months-long release of therapeutic agents (such as dexamethasone) from a single injection. Offered as a licensable platform to pharmaceutical partners; ProMed Pharma acquired an option to license the underlying intellectual property in April 2024.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-06-17
Description

SpineThera, Inc. entered into a collaboration with Mayo Clinic in June 2024 to advance solutions in substance abuse disorder treatment, expanding beyond the company's core focus on back pain treatment.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2024-04-03
Description

ProMed Pharma acquired SpineThera's manufacturing capabilities and obtained an option to license intellectual property in April 2024, enabling ProMed to leverage SpineThera's production capabilities while SpineThera gains access to ProMed's manufacturing infrastructure.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

SpineThera operates as a portfolio company under Frenelle Pharma, a hub-and-spoke pharmaceutical model company. Frenelle Pharma officially launched in January 2025, with SpineThera representing one of its key pipeline assets.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Pacira is a specialty pharmaceutical company known for sustained-release injectable pain therapies (e.g., Exparel). It is the most directly comparable peer to SpineThera given the overlap in sustained-release injectable technology and non-opioid pain focus.

TypeDirect peer
Description

Heron develops sustained-release and long-acting injectable therapeutics for postoperative pain and other indications (e.g., Zynrelef, Sustol). The company's extended-release drug delivery approach for pain management closely parallels SpineThera's Faros™ technology strategy.

TypeDirect peer
Description

Collegium is a specialty pharmaceutical company focused on responsible pain management, including abuse-deterrent and non-opioid pain products. It targets overlapping physician channels (pain specialists, prescribers) as SpineThera's SX600.

TypeDirect peer
Description

Scilex Holding is a specialty pharma company focused on non-opioid pain management, including sciatica and lower back pain (e.g., ZTlido, SP-102). It is a direct competitor targeting the same lumbar radicular pain indication via interventional/injectable therapies.

TypeDirect peer
Description

Cara Therapeutics develops therapeutics for pruritus and pain, with focus on novel peripherally acting kappa opioid receptor agonists. It operates in the same clinical-stage pain therapeutics space as SpineThera with similar development and commercialization challenges.

TypeDirect peer
Description

Trevena is a clinical-stage pharmaceutical company developing innovative pain therapeutics, including Olinvyk (an IV analgesic). It overlaps with SpineThera in developing differentiated, non-opioid pain management options for acute and chronic indications.

TypeDirect peer
Description

Tersera is a specialty pharmaceutical company focused on pain management, oncology, and supportive care. Its pain franchise targets similar specialist prescribers and represents commercial overlap with a future SX600 launch.

TypeBroad incumbent
Description

Pfizer is a large incumbent pharmaceutical company with a broad pain portfolio (including Lyrica and Celebrex historically) and deep commercialization capability. It represents both a potential acquirer of SpineThera and a broad competitive threat once SX600 reaches market.

TypeBroad incumbent
Description

Vertex is a large pharmaceutical company that has publicly expanded into acute and chronic pain (e.g., VX-548/suzetrigine). Although Vertex's modality differs (oral NaV1.8 inhibitor), it is competing in the same non-opioid pain treatment market SpineThera targets.

TypeBroad incumbent
Description

Lilly is a large pharmaceutical incumbent with an expanding pain and neuroscience portfolio. As a potential strategic acquirer or competitor, Lilly represents the kind of large-pharma counterparty likely to evaluate SpineThera's first-in-class epidural asset.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SpineThera

Pain Management Pharmaceuticalsspinethera.com

SpineThera is a clinical-stage pharmaceutical company developing SX600, a sustained-release dexamethasone epidural injection using its proprietary Faros™ drug delivery platform to treat lumbar radicular pain (sciatica), an indication with no current FDA-approved drug therapy.

What SpineThera does

SpineThera is a clinical-stage pharmaceutical company developing sustained-release injectable drugs for pain management. Its lead asset, SX600, is a novel formulation of dexamethasone built on the proprietary Faros™ drug delivery platform, designed to provide months-long sustained release from a single epidural injection for the treatment of lumbar radicular pain (sciatica). The company is led by founder and CEO Jeff Missling and Chief Medical Officer William Houghton. Notably, no FDA-approved drug currently exists for epidural injection to treat lumbar radicular pain, positioning SX600 as a potential first-in-class therapy for what the company characterizes as the most common cause of disability in the United States and the most expensive indication in healthcare.

The company's technology foundation is the Faros™ sustained-release drug delivery platform, protected by 7 issued US patents as of November 2024. SX600 completed Phase 2 clinical trials demonstrating clinically meaningful and durable pain reduction from a single injection; however, an additional non-rodent toxicology study is required before opening an IND to advance into Phase 3. SpineThera operates as a subsidiary within Frenelle Pharma's hub-and-spoke model, alongside portfolio companies Frenelle PBC and Anumio. In April 2024, SpineThera divested its manufacturing capabilities to ProMed Pharma while retaining an option for IP licensing, indicating a transition to an asset-light, R&D-focused operating model.

SpineThera's business model is pre-commercial and currently revenue-free. Historical funding has come from exempt securities offerings (a $4M Form D filed in June 2021, with $1.215M sold) and a $5M Department of Defense grant awarded in April 2022. Upon any future FDA approval, distribution is expected to flow through specialty pharmacies, hospital formularies, and pain management clinics. End customers are patients with lumbar radicular pain and the pain management specialists who administer treatment. The company has begun exploring adjacent applications of the Faros™ platform through a June 2024 collaboration with Mayo Clinic in substance abuse disorder treatment, signaling intent to monetize the delivery technology beyond its original indication.

SpineThera firmographics

Firmographics
Name
SpineThera
Legal name
SpineThera, Inc.
Website
https://spinethera.com
Company type
Private
Founded year
2012
Operating status
Operating
Headcount range
1–10 employees
Short description
SpineThera is a clinical-stage pharmaceutical company developing SX600, a sustained-release dexamethasone epidural injection using its proprietary Faros™ drug delivery platform to treat lumbar radicular pain (sciatica), an indication with no current FDA-approved drug therapy.
Ownership category
akta.pro rank

SpineThera industry classification

Industry
Product category
Pain Management Pharmaceuticals
akta.pro industry
PRIMARYHLAIAAAN
Pain Management & Anesthesiology Pharmaceuticals
Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals
SECONDARYHLAKAIAM
Pain Medicine (Interventional/Neuropathic Pain)

Keywords

  • Sustained-release pharmaceuticals
  • Epidural injection therapy
  • Lumbar pain treatment
  • Drug delivery platforms
  • Corticosteroid formulations

Where SpineThera is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Markets served

SpineThera business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Revenue will be generated through sales of FDA-approved pharmaceutical products, specifically SX600 for lumbar radicular pain treatment upon regulatory approval.

SpineThera product offering

Product offering

Core offering

SpineThera is developing SX600, a novel sustained-release formulation of dexamethasone administered as a single epidural injection for the treatment of lumbar radicular pain (sciatica). The product is built on the proprietary Faros™ drug delivery platform, which enables months-long therapeutic release of dexamethasone from a single injection, eliminating the need for repeated corticosteroid procedures. SX600 has completed Phase 2 clinical trials demonstrating clinically meaningful and durable pain reduction.

Product overview

SpineThera is a clinical-stage pharmaceutical company that operates as a subsidiary of Frenelle Pharma. The company is developing SX600, a novel formulation of dexamethasone utilizing the proprietary Faros™ sustained-release drug delivery technology platform. SX600 is designed as an epidural injection for lumbar radicular pain (sciatica) and has completed Phase 2 clinical trials. Currently, there is no FDA-approved drug for epidural injection to treat lumbar radicular pain, representing a potential first-in-class opportunity. The company's pipeline progresses from preclinical through Phase 3 stages.

Differentiator

Problem solved

Functional benefit

Brands

  • Faros™: Proprietary technology platform used for sustained-release drug delivery in SpineThera's lead asset SX600.
  • SX600

Products and services

  • SX600 Novel sustained-release formulation of dexamethasone using Faros™ technology, developed as a single epidural injection for the treatment of lumbar radicular pain (sciatica). Designed to deliver months-long sustained-release dexamethasone from a single injection, eliminating the need for repeated corticosteroid procedures. Completed Phase 2 clinical trials with positive efficacy data. Intended for prescription and administration by pain management specialists and healthcare providers.
  • Faros™ Drug Delivery Technology Platform Proprietary sustained-release drug delivery technology platform enabling months-long release of therapeutic agents (such as dexamethasone) from a single injection. Offered as a licensable platform to pharmaceutical partners; ProMed Pharma acquired an option to license the underlying intellectual property in April 2024.

Quantifiable outcome

  • Clinically meaningful and durable reduction in lumbar radicular pain from a single epidural injection in Phase 2 trial

Companies that use SpineThera

Customer profile

Segments2 records

Ideal customer profiles2 records

SpineThera technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

SpineThera partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • Mayo CliniccoreStrategic or Co-development Partner · 17 June 2024SpineThera, Inc. entered into a collaboration with Mayo Clinic in June 2024 to advance solutions in substance abuse disorder treatment, expanding beyond the company's core focus on back pain treatment.
  • ProMed PharmacoreOEM/ Whitelabel/ Licensing Partner · 3 April 2024ProMed Pharma acquired SpineThera's manufacturing capabilities and obtained an option to license intellectual property in April 2024, enabling ProMed to leverage SpineThera's production capabilities while SpineThera gains access to ProMed's manufacturing infrastructure.
  • Frenelle PharmacoreStrategic or Co-development PartnerSpineThera operates as a portfolio company under Frenelle Pharma, a hub-and-spoke pharmaceutical model company. Frenelle Pharma officially launched in January 2025, with SpineThera representing one of its key pipeline assets.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

SpineThera competitors and assessment

Company assessment

Direct peers

  • Pacira Biosciences: Pacira is a specialty pharmaceutical company known for sustained-release injectable pain therapies (e.g., Exparel). It is the most directly comparable peer to SpineThera given the overlap in sustained-release injectable technology and non-opioid pain focus.
  • Heron Therapeutics: Heron develops sustained-release and long-acting injectable therapeutics for postoperative pain and other indications (e.g., Zynrelef, Sustol). The company's extended-release drug delivery approach for pain management closely parallels SpineThera's Faros™ technology strategy.
  • Collegium Pharmaceutical: Collegium is a specialty pharmaceutical company focused on responsible pain management, including abuse-deterrent and non-opioid pain products. It targets overlapping physician channels (pain specialists, prescribers) as SpineThera's SX600.
  • Scilex Holding: Scilex Holding is a specialty pharma company focused on non-opioid pain management, including sciatica and lower back pain (e.g., ZTlido, SP-102). It is a direct competitor targeting the same lumbar radicular pain indication via interventional/injectable therapies.
  • Cara Therapeutics: Cara Therapeutics develops therapeutics for pruritus and pain, with focus on novel peripherally acting kappa opioid receptor agonists. It operates in the same clinical-stage pain therapeutics space as SpineThera with similar development and commercialization challenges.
  • Trevena: Trevena is a clinical-stage pharmaceutical company developing innovative pain therapeutics, including Olinvyk (an IV analgesic). It overlaps with SpineThera in developing differentiated, non-opioid pain management options for acute and chronic indications.
  • Tersera Therapeutics: Tersera is a specialty pharmaceutical company focused on pain management, oncology, and supportive care. Its pain franchise targets similar specialist prescribers and represents commercial overlap with a future SX600 launch.

Broad incumbents

  • Pfizer: Pfizer is a large incumbent pharmaceutical company with a broad pain portfolio (including Lyrica and Celebrex historically) and deep commercialization capability. It represents both a potential acquirer of SpineThera and a broad competitive threat once SX600 reaches market.
  • Vertex Pharmaceuticals: Vertex is a large pharmaceutical company that has publicly expanded into acute and chronic pain (e.g., VX-548/suzetrigine). Although Vertex's modality differs (oral NaV1.8 inhibitor), it is competing in the same non-opioid pain treatment market SpineThera targets.
  • Eli Lilly: Lilly is a large pharmaceutical incumbent with an expanding pain and neuroscience portfolio. As a potential strategic acquirer or competitor, Lilly represents the kind of large-pharma counterparty likely to evaluate SpineThera's first-in-class epidural asset.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

SpineThera social profiles

Digital presence

SpineThera financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SpineThera leadership team

Management profile

Number of profiles

Profiles2 records

SpineThera funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SpineThera M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpineThera

What does SpineThera do?

SpineThera is developing SX600, a novel sustained-release formulation of dexamethasone administered as a single epidural injection for the treatment of lumbar radicular pain (sciatica). The product is built on the proprietary Faros™ drug delivery platform, which enables months-long therapeutic release of dexamethasone from a single injection, eliminating the need for repeated corticosteroid procedures. SX600 has completed Phase 2 clinical trials demonstrating clinically meaningful and durable pain reduction.

Is SpineThera a public or private company?

SpineThera is a private company. It is classified as corporate owned and is currently operating.

When was SpineThera founded?

SpineThera was founded in 2012. It employs 1 to 10 people.

Where is SpineThera based?

SpineThera is headquartered in Minneapolis, United States, in the North America region.

How does SpineThera make money?

One revenue line is on record: pharmaceutical Product Sales.

Who are SpineThera's main competitors?

Direct peers on record are Pacira Biosciences, Heron Therapeutics, Collegium Pharmaceutical, Scilex Holding, Cara Therapeutics, Trevena and Tersera Therapeutics. Broad incumbents are Pfizer, Vertex Pharmaceuticals and Eli Lilly.

Does SpineThera have an API?

No public API is recorded for SpineThera.

What industry is SpineThera in?

SpineThera's product category is Pain Management Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAN, Pain Management & Anesthesiology Pharmaceuticals, with a secondary code of HLAKAIAM, Pain Medicine (Interventional/Neuropathic Pain).

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
YahooSpineThera, Inc. to Collaborate With Mayo Clinic to Advance Solutions in Substance Abuse Disorder TreatmentSpineThera, Inc. entered a know-how agreement with Mayo Clinic to develop long-acting injectable drugs for substance abuse disorder treatment. The collaboration, led by CEO Jeff Missling and Mayo Clinic's Tyler Oesterle, aims to improve outcomes and access. Mayo Clinic has a financial interest in the technology.Business Wire BlogProMed Pharma Acquires SpineThera Manufacturing Capabilities and an Option to License Intellectual PropertyProMed Pharma acquired SpineThera's cGMP manufacturing assets and an option to license its microsphere intellectual property. The deal adds biodegradable microparticle development to ProMed's portfolio, with financial terms undisclosed. SpineThera will remain a customer, manufacturing SX600 in the same cleanroom.BioSpaceDoug Drysdale and Dr. Shaheen Lakhan Join SpineThera BoardSpineThera announced that Doug Drysdale and Dr. Shaheen Lakhan joined its board to support SX600's clinical development. The company is nearing completion of the SALIENT trial for its dexamethasone formulation for sciatica. The board members will help guide next steps and expand the product pipeline.BioSpaceSpineThera Awarded $5 Million Grant from Department of DefenseSpineThera received a $4.97 million grant from the U.S. Department of Defense to support development of SX600, a sustained-release dexamethasone for lumbar radiculopathy. The grant covers nonclinical toxicity testing and manufacturing scale-up, bringing total non-dilutive funding to over $18.5 million.SecSEC FORM DSpineThera, Inc. filed a Form D with the SEC for an exempt securities offering under Rule 506(b) with a total offering amount of $4 million. The company has sold $1.215 million of these securities to 12 investors as of June 30, 2021, with $2.785 million remaining.MedCity NewsThree “hits” on biopharma market trends at mcINVESTMedCity INVEST in Chicago featured a panel on biopharma investment trends, including Amgen's money-back guarantee for Repatha and private company valuations lagging public ones. Early-stage startups received DoD funding, with Third Coast Therapeutics and SpineThera cited. The DoD's CDMRP website listed new grant opportunities.